Gene: JARID2

3720
JMJ
jumonji and AT-rich interaction domain containing 2
protein-coding
6p22.3
Ensembl:ENSG00000008083 MIM:601594 Vega:OTTHUMG00000014293 UniprotKB:Q92833
NC_000006.12
SNP Mapped
2   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.702e-1 (AD)  4.819e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs760659chr6:15504358 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs707838chr6:15352012 (GRCh38.p7)G>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg09202659chr6:15380565JARID21.500e-10Smoking27651444
cg16248435chr6:15358299JARID21.100e-9Smoking27651444
cg26405097chr6:15428301JARID25.940e-8Alcohol consumption der day27843151

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CPSF70.833
ZBTB430.829
TNRC6A0.818
CLEC16A0.817
CCDC930.812
PHF120.808
PTCD30.804
POGZ0.801
MTMR30.801
SNRNP2000.799

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.549
OR4F29-0.528
KLRC2-0.32
CD8B-0.298
GZMK-0.297
GZMA-0.269
CD3G-0.263
MTRNR2L9-0.252
KRTAP1-1-0.25
IAPP-0.25

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0109142,4-diaminotoluene"2,4-diaminotoluene results in decreased expression of JARID2 mRNA"20713471
C0235142,6-dinitrotoluene"2,6-dinitrotoluene results in decreased expression of JARID2 mRNA"20406850
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JARID2 mRNA"27188386
C517041(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)"(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) results in increased expression of JARID2 mRNA"19561079
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JARID2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of JARID2 mRNA29067470
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of JARID2 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of JARID2 gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of JARID2 mRNA19770486
C006632arsenic trioxideJARID2 protein results in increased susceptibility to arsenic trioxide20707922
D001280AtrazineAtrazine results in decreased expression of JARID2 mRNA25929836
C547126AZM551248AZM551248 results in decreased expression of JARID2 mRNA22323515
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of JARID2 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of JARID2 mRNA19770486
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of JARID2 mRNA"20382639
C006780bisphenol Abisphenol A results in decreased expression of JARID2 mRNA25181051
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in increased expression of JARID2 mRNA20147733
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of JARID2 gene20938992
D002945CisplatinCisplatin results in decreased expression of JARID2 mRNA25270620
D004114DimethadioneDimethadione results in increased expression of JARID2 mRNA26311034
C024629dimethyl phthalatedimethyl phthalate results in increased expression of JARID2 mRNA26924002
C118739entinostatentinostat results in increased expression of JARID2 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JARID2 mRNA"27188386
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of JARID2 mRNA22079256
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of JARID2 mRNA17555576
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of JARID2 mRNA17942748
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of JARID2 mRNA17942748
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of JARID2 gene20938992
D005557FormaldehydeFormaldehyde results in decreased expression of JARID2 mRNA20655997|2341626
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of JARID2 mRNA17183730
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased expression of JARID2 mRNA18951874
C013038hydroxyhydroquinonehydroxyhydroquinone results in increased expression of JARID2 mRNA17572062
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of JARID2 mRNA25613284
D007545IsoproterenolIsoproterenol results in decreased expression of JARID2 mRNA20003209
D008070LipopolysaccharidesLipopolysaccharides results in decreased expression of JARID2 mRNA12057914
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of JARID2 gene20938992
D008727MethotrexateMethotrexate affects the expression of JARID2 mRNA18502557
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of JARID2 mRNA23649840
C016599mono-(2-ethylhexyl)phthalatemono-(2-ethylhexyl)phthalate results in decreased expression of JARID2 mRNA22401849
C517284monomethyl phthalatemonomethyl phthalate affects the expression of JARID2 mRNA26924002
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of JARID2 mRNA"25554681
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of JARID2 mRNA25729387
C016030pantogabpantogab results in decreased expression of JARID2 mRNA17379144
C568608PCI 5002[PCI 5002 co-treated with Zinc] results in increased expression of JARID2 mRNA18593933
C101814perfluoro-n-undecanoic acidperfluoro-n-undecanoic acid results in decreased expression of JARID2 mRNA23602845
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of JARID2 mRNA19710929
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of JARID2 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of JARID2 mRNA22079256
D011791QuartzQuartz results in decreased expression of JARID2 protein27917503
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in decreased expression of JARID2 mRNA21427059
D017632Asbestos, Serpentine"Asbestos, Serpentine results in increased expression of JARID2 mRNA"24160326
D012822Silicon DioxideSilicon Dioxide results in decreased expression of JARID2 protein27917503
D012834SilverSilver results in decreased expression of JARID2 mRNA27131904
D013739TestosteroneTestosterone results in decreased expression of JARID2 mRNA20403060
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of JARID2 mRNA21570461
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of JARID2 mRNA17942748
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects the expression of JARID2 mRNA25613284
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of JARID2 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of JARID2 mRNA25729387
D014212TretinoinTretinoin results in decreased expression of JARID2 mRNA22906706
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of JARID2 mRNA17183730
D014635Valproic AcidValproic Acid affects the expression of JARID2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of JARID2 mRNA23179753
D014635Valproic AcidValproic Acid results in decreased expression of JARID2 mRNA19136453|2142705
D014638VanadatesVanadates results in increased expression of JARID2 mRNA22714537
D024483Vitamin K 3Vitamin K 3 affects the expression of JARID2 mRNA20044591
D015032Zinc[PCI 5002 co-treated with Zinc] results in increased expression of JARID2 mRNA18593933

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IEA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0001227transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IBA21873635  
GO:0001227transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IEA-  
GO:0003682chromatin binding-IBA21873635  
GO:0003682chromatin binding-ISS-  
GO:0008134transcription factor binding-IEA-  
GO:0032452histone demethylase activity-IBA21873635  
GO:0032452histone demethylase activityNOTISS-  
GO:0034647histone demethylase activity (H3-trimethyl-K4 specific)-IBA21873635  
GO:0035064methylated histone binding-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IEA-  
GO:0001889liver development-IEA-  
GO:0006325chromatin organization-IEA-  
GO:0006351transcription, DNA-templated-IEA-  
GO:0007417central nervous system development-TAS8894700  
GO:0010614negative regulation of cardiac muscle hypertrophy-IEA-  
GO:0031061negative regulation of histone methylation-ISS-  
GO:0045814negative regulation of gene expression, epigenetic-TAS-  
GO:0045892negative regulation of transcription, DNA-templated-ISS-  
GO:0048536spleen development-IEA-  
GO:0048538thymus development-IEA-  
GO:0048863stem cell differentiation-ISS-  
GO:0051574positive regulation of histone H3-K9 methylation-ISS-  
GO:0060044negative regulation of cardiac muscle cell proliferation-IEA-  
GO:1990830cellular response to leukemia inhibitory factor-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA20075857  
GO:0005654nucleoplasm-TAS-  
GO:0005739mitochondrion-IDA-  
GO:0035097histone methyltransferase complex-IBA21873635  
GO:0035097histone methyltransferase complex-ISS-  
GO:0035098ESC/E(Z) complexcolocalizes_withIDA20075857  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-212165Epigenetic regulation of gene expressionTAS
R-HSA-212300PRC2 methylates histones and DNATAS
R-HSA-74160Gene expression (Transcription)TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal